ALB and sarcoma: Patients who have not been included in the main analysis, that is, those who have not received 3 trabectedin cures for any cause, as well as those who progressed before the third cycle, were characterized, as expected, by poor general condition (high ECOG performance status, low albumin levels, elevation of alkaline phosphatase ...) and aggressiveness of sarcoma (short interval between initial diagnosis and onset of trabectedin).